Join us for our two part Science Series, designed specifically for in-house lawyers working within life sciences companies. This unique programme aims to bridge the gap between legal expertise and scientific innovation, providing lawyers with user-friendly overview of the science underlying some cutting-edge technologies.

Each session will give an overview of the science and explanation of the jargon, followed by related legal considerations. Aimed at those who would like to deepen their understanding of the scientific principles driving their company's technological advancements - whether you are new to the field or looking to refresh your knowledge.

Series Overview

Venue: London (in person)

Timings: 5.00 pm to 6.30 pm followed by networking drinks

View an outline of the upcoming sessions below.

ADCs and radiopharmaceuticals - Wednesday 18 September 2024

Antibody-drug conjugates (ADCs) are revolutionising targeted therapy, particular for cancer, by harnessing the specificity of antibodies to deliver drugs directly to target cells. There is also currently a lot of attention on radiopharmaceuticals, which pair radioactive particles with antibodies or other targeted carrier molecules, and have uses in diagnostic imaging as well as therapeutics.

In this session, Bristows will explore the science behind ADCs and radiopharmaceuticals, and examine the legal considerations relevant to these technologies.

Meet our speakers

Claire Phipps-Jones, Of Counsel, Bristows

Louisa Jacobs, Senior Associate, Bristows

Jamie Hatzel, Associate, Bristows (Legal considerations)

Oncolytic viruses and cancer vaccines - Wednesday 2 October 2024

Oncolytic viruses and cancer vaccines are emerging as promising treatments in oncology. Oncolytic viruses selectively infect and destroy cancer cells, while therapeutic cancer vaccines stimulate the adaptative immune system against specific malignant cells so the immune system can destroy them. There is growing interest in their potential to complement traditional therapies like surgery, chemotherapy, and radiation.

In this session, Bristows will delve into the science behind oncolytic viruses and therapeutic cancer vaccines, exploring their mechanisms and applications, along with some legal considerations relevant to these technologies.